Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.

ABSTRACT: Hepatitis C virus (HCV)-induced end-stage liver disease is the major indication for liver transplantation (LT). However, reinfection of the liver graft is still common, especially in patients with detectable viral load at the time of LT. Limited data are available on direct-acting antivirals in the transplant setting for prevention of graft infection. The human hepatitis C immunoglobulin (HCIG) Civacir is an investigational drug that is currently being developed in an ongoing phase 3 clinical trial assessing its safety and efficacy at preventing HCV recurrence after liver transplantation (LT) in the United States. Using well-characterized patient-derived HCV variants selected during LT, we studied the molecular mechanism of action of Civacir. Inhibition of HCV infection was studied using i

SUBMITTER: Tawar RG 

PROVIDER: S-EPMC7615276 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature